Rosetta Aims to Use miRNAs as Biomarkers for Pharmaceutical R&D

Rosetta's president and CEO also noted that the company continues to work in the miRNA therapeutics space, but indicated that its collaboration with Regulus Therapeutics to develop a liver cancer drug has officially ended.

Full-text access for premium subscribers only. Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.